GlassScriptPhysician profile
Jennifer R Epperson
NPI 1417251844
$1,824.66
in general payments reported to CMS, 2019-2025
26 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $578 · 2022: $734 · 2023: $91.77 · 2024: $55.35 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $512.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $318.52 | 2021-2025 | Lifevest |
| Boston Scientific Corporation | $264.52 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $221.76 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $219.79 | 2021-2025 | Camzyos |
| Sanofi-Aventis U.S. LLC | $90.67 | 2022-2024 | |
| Pfizer INC. | $86.87 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $77.09 | 2022-2025 | |
| Esperion Therapeutics, INC. | $73.30 | 2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $67.02 | 2021-2022 | |
| Amgen INC. | $46.73 | 2021-2025 | Repatha |
| Novo Nordisk INC | $44.92 | 2022 | |
| Abbott Laboratories | $40.43 | 2021-2025 | Jot Dx |
| Idorsia Pharmaceuticals US INC | $30.13 | 2025 | Tryvio |
| Lantheus Medical Imaging, INC. | $29.27 | 2022 | |
| Astellas Pharma US INC | $26.58 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.70 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $19.46 | 2024 | Farxiga |
| Lexicon Pharmaceuticals, INC. | $19.44 | 2023 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.88 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.74 | 2021 | |
| Chiesi USA, INC. | $15.46 | 2022 | |
| W. L. Gore & Associates, INC. | $15.32 | 2021 | |
| Philips North America LLC | $15.10 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Amarin Pharma, INC. | $14.85 | 2021 | |
| Lilly USA, LLC | $14.43 | 2025 | Zepbound, Mounjaro |
| Akcea Therapeutics, INC. | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Epperson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.